HER3-targeting ADCs and TROP2-targeting ADCs have shown promising efficacy in phase 1 and 2 studies of patients with EGFR-mutated NSCLC who progressed after EGFR -TKI and platinum-based chemotherapy (38–40). Here, TACSTD2 is linked to non-small cell lung carcinoma.